HeartBeam (NASDAQ: BEAT) has announced the launch of a pilot study focused on testing its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. The study marks a significant step in the development of the patch, which aims to address limitations in current ambulatory monitoring technologies.
Coronary artery disease remains a leading cause of death worldwide, often progressing silently until a major cardiac event occurs. According to the company, current patch-based ambulatory monitors are unable to detect ischemia or provide clinical-grade insights over extended periods. The HeartBeam patch is designed to change that by enabling on-demand 12-lead ECG recordings, potentially offering a new tool for early detection of inadequate blood flow to the heart.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could transform how we monitor patients at risk of coronary artery disease.”
The pilot study is a crucial step in validating the patch’s ability to detect ischemia, which could pave the way for it to enter the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets. If successful, the technology could provide physicians with a non-invasive, patient-friendly method for continuous monitoring and early intervention.
Forward-looking statements in the release highlight potential risks and uncertainties, as detailed in the company's filings with the SEC. More information about HeartBeam and the study can be found in the company’s newsroom at https://ibn.fm/BEAT.
This announcement underscores the growing interest in innovative cardiac monitoring solutions that can deliver hospital-grade data in ambulatory settings. The study results will be closely watched by investors and healthcare providers alike, as they could signal a shift in how coronary artery disease is managed outside of clinical environments.
